| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Clinical and Translational Research |
| Article Title |
FDX1 as a novel biomarker and treatment target for stomach adenocarcinoma
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Xian-Ze Xie, Lei Zuo, Wei Huang, Qiao-Mei Fan, Ya-Yun Weng, Wen-Dong Yao, Jia-Li Jiang and Jia-Qi Jin |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| The Medical and Health Research Project of Zhejiang Province |
2021RC097 |
|
| Corresponding Author |
Jia-Qi Jin, BSc, Pharmacist, Department of Pharmacy, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), No. 9 Road, 9 Dajie, Qiantang District, Hangzhou 310018, Zhejiang Province, China. 13806509322@163.com |
| Key Words |
Stomach adenocarcinoma disease; Copper death; FDX1; prognostic biomarkers; Cuproptosis-related genes |
| Core Tip |
This study explores the novel link between cuproptosis-related genes (CRGs) and stomach adenocarcinoma (STAD), identifying FDX1 as a potential biomarker and therapeutic target. Utilizing comprehensive analyses, including Gene Set Enrichment Analysis and Least Absolute Shrinkage and Selection Operator regression, we categorized STAD patients into high and low risk based on CRG scores. FDX1, along with two other genes, demonstrated significant diagnostic and prognostic potential, suggesting a new avenue for targeted therapies in gastric cancer treatment. |
| Publish Date |
2024-06-30 07:39 |
| Citation |
<p>Xie XZ, Zuo L, Huang W, Fan QM, Weng YY, Yao WD, Jiang JL, Jin JQ. FDX1 as a novel biomarker and treatment target for stomach adenocarcinoma. <i>World J Gastrointest Surg</i> 2024; 16(6): 1803-1824</p> |
| URL |
https://www.wjgnet.com/1948-9366/full/v16/i6/1803.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v16.i6.1803 |
